

# Author Index Volume 32 (2012)

The issue number is given in front of the pagination

- Abekasis, M., see Nachmany, H. (4) 211–220  
Adane, S., see Cherbal, F. (6) 343–353  
Amer, M.A., see El-Tayeh, S.F. (4) 255–263  
Antczak, A., see Ciebiada, M. (5) 329–335  
Arjun, P., see Sharma, A. (2) 101–107  
Arneric, N., see Franko, A. (2) 123–131  
Auewarakul, C., see Sinthuwiwat, T. (2) 115–121
- Baba, R.A., H.F. Bhat, L.A. Wani, M. Bashir, M.M. Wani, S.K. Qadri and F.A. Khanday, E3B1/ABI-1 isoforms are down-regulated in cancers of human gastrointestinal tract (4) 273–279  
Bain, S.C., see Prior, S.L. (6) 363–369  
Bakour, R., see Cherbal, F. (6) 343–353  
Balaram, P., see Jacob, J. (6) 371–381  
Bashir, M., see Baba, R.A. (4) 273–279  
Batra, N., see Birbian, N. (5) 301–308  
Bazzaz, J.T., see Tabaripour, R. (4) 241–246  
Bello, M.G., see Esparragón, F.R. (4) 231–239  
Beltrán-Miranda, C.P., see Brambila-Tapia1, A.J.L. (2) 109–114  
Berg, A., see Yu, W. (2) 83–91  
Bessong, P.O., see Masebe, T.M. (1) 43–50  
Bhat, H.F., see Baba, R.A. (4) 273–279  
Birbian, N., J. Singh, S.K. Jindal, A. Joshi, N. Batra and N. Singla, Association of the wild-type A/A genotype of MBL2 codon 54 with asthma in a North Indian population (5) 301–308  
Biselli, J.M., see Zampieri, B.L. (2) 73–81  
Boualga, K., see Cherbal, F. (6) 343–353  
Brambila-Tapia1, A.J.L., J. Durán-González, L. Sandoval-Ramírez, J.P. Mena, M. Salazar-Páramo, J.I. Gámez-Nava, L. González-López, B. Lazalde-Medina, N.O. Dávalos, V. Peralta-Leal, M.V. del Mercado, C.P. Beltrán-Miranda and I.P. Dávalos, MTHFR C677T, MTHFR A1298C, and OPG A163G polymorphisms in Mexican patients with rheumatoid arthritis and osteoporosis (2) 109–114  
Bulvik, S., see Nachmany, H. (4) 211–220
- Butler, M.G., see Dodani, S. (1) 9–19
- ÇanakçI, C.F., see Sezer, U. (3) 165–172  
Carnero, A., see Molina-Pinelo, S. (4) 221–230  
Carvalho, V.M., see Zampieri, B.L. (2) 73–81  
Chang, C.-C., see Cheng, C.-C. (1) 21–31  
Chang, J., see Cheng, C.-C. (1) 21–31  
Chatterjee, A., A. Rathore, S. Vidyant, K. Kakkar and T.N. Dhole, Chemokines and Chemokine Receptors in susceptibility to HIV-1 infection and progression to AIDS (3) 143–151  
Chen, L., L. Su, J. Li, Y. Zheng, B. Yu, Y. Yu, M. Yan, Q. Gu, Z. Zhu and B. Liu, Hypermethylated *FAM5C* and *MYLK* in serum as diagnosis and pre-warning markers for gastric cancer (3) 195–202  
Chen, L.-Y., see Cheng, C.-C. (1) 21–31  
Chen, R.-C., see Ju, C.-R. (5) 281–287  
Chen, W.-T., see Javidrooz, M. (5) 309–320  
Cheng, C.-C., J. Chang, L.-Y. Chen, A.-S. Ho, K.-J. Huang, S.-C. Lee, F.-D. Mai and C.-C. Chang, Human neutrophil peptides 1-3 as gastric cancer tissue markers measured by MALDI-imaging mass spectrometry: Implications for infiltrated neutrophils as a tumor target (1) 21–31  
Cherbal, F., N. Salhi, R. Bakour, S. Adane, K. Boualga and P. Maillet, *BRCA1* and *BRCA2* unclassified variants and missense polymorphisms in algerian breast/ovarian cancer families (6) 343–353  
Chiabai, M.A., T.C.L. Lins, R. Pogue and R.W. Pereira, Population analysis of pharmacogenetic polymorphisms related to acute lymphoblastic leukemia drug treatment (4) 247–253  
Christgen, M., see Knoener, M. (6) 337–342  
Çiçek, Y., see Sezer, U. (3) 165–172  
Ciebiada, M., P. Górski and A. Antczak, Eicosanoids in exhaled breath condensate and bronchoalveolar lavage fluid of patients with primary lung cancer (5) 329–335  
Cieslarova, B., see Dostalikova-Cimburova, M. (1) 65–72

- Cilenšek, I., S. Mankoč, M.G. Petrovič and D. Petrovič, GSTT1 null genotype is a risk factor for diabetic retinopathy in Caucasians with type 2 diabetes, whereas GSTM1 null genotype might confer protection against retinopathy (2) 93–99
- Clark, A.R., see Prior, S.L. (6) 363–369
- Companiononi, O., see Esparragón, F.R. (4) 231–239
- Cordeiro, J.A., see Zampieri, B.L. (2) 73–81
- Das, G., see Sadhukhan, T. (6) 355–362
- Das, S.K., see Sadhukhan, T. (6) 355–362
- Dávalos, I.P., see Brambila-Tapia1, A.J.L. (2) 109–114
- Dávalos, N.O., see Brambila-Tapia1, A.J.L. (2) 109–114
- de Rosso, A.L.Z., see Moura, K.C.V. (3) 173–178
- del Mercado, M.V., see Brambila-Tapia1, A.J.L. (2) 109–114
- Devanoorkar, A., C.D. Dwarakanath, G. Gundanavar, R. Kathariya and S.R. Patil, Evaluation of serum resistin levels in periodontal health and disease and effects of non surgical periodontal therapy on its levels (5) 289–294
- Dhole, T.N., see Chatterjee, A. (3) 143–151
- Dodani, S., R. Henkhaus, L. Dong and M.G. Butler, Apo lipoprotein A1 gene polymorphisms predict cardio-metabolic risk in South Asian immigrants (1) 9–19
- Dodic-Fikfak, M., see Franko, A. (2) 123–131
- Dolzan, V., see Franko, A. (2) 123–131
- Dong, L., see Dodani, S. (1) 9–19
- Dostalíkova-Cimburova, M., K. Kratka, J. Stransky, I. Putova, B. Cieslarova and J. Horak, Iron overload and HFE gene mutations in Czech patients with chronic liver diseases (1) 65–72
- Douki, M.R.E., see Tabaripour, R. (4) 241–246
- Driss, A., N.O. Wilson, K. Mason, H.I. Hyacinth, J.M. Hibbert, G.R. Serjeant and J.K. Stiles, Elevated IL-1 $\alpha$  and CXCL10 serum levels occur in patients with homozygous sickle cell disease and a history of acute splenic sequestration (5) 295–300
- Durán-González, J., see Brambila-Tapia1, A.J.L. (2) 109–114
- Dwarakanath, C.D., see Devanoorkar, A. (5) 289–294
- El-Houseini, M.E., see El-Tayeh, S.F. (4) 255–263
- Elshemey, W.M., see El-Tayeh, S.F. (4) 255–263
- El-Sherbini, M., see El-Tayeh, S.F. (4) 255–263
- El-Tayeh, S.F., T.D. Hussein, M.E. El-Houseini, M.A. Amer, M. El-Sherbini and W.M. Elshemey, Serological biomarkers of hepatocellular carcinoma in Egyptian patients (4) 255–263
- Esparragón, F.R., O. Companiononi, M.G. Bello, N.B. Ríos and J.C.R. Pérez, Replication of relevant SNPs associated with cardiovascular disease susceptibility obtained from GWAs in a case-control study in a Canarian population (4) 231–239
- Fang, W., see Yu, F. (5) 321–327
- Franke, A., see Yu, W. (2) 83–91
- Franko, A., V. Dolzan, V. Kovac, N. Arneric and M. Dodic-Fikfak, Soluble mesothelin-related peptides levels in patients with malignant mesothelioma (2) 123–131
- Galanko, J., see Hoyo, C. (2) 133–141
- Gámez-Nava, J.I., see Brambila-Tapia1, A.J.L. (2) 109–114
- Garg, N., see Mishra, A. (1) 33–41
- Goloni-Bertollo, E.M., see Zampieri, B.L. (2) 73–81
- González-López, L., see Brambila-Tapia1, A.J.L. (2) 109–114
- Górski, P., see Ciebiada, M. (5) 329–335
- Gu, Q., see Chen, L. (3) 195–202
- Gümüs, Z.H., see Suresh, A. (1) 51–64
- Gundanavar, G., see Devanoorkar, A. (5) 289–294
- Guo, S., see Yu, F. (5) 321–327
- Ha, S.-A., see Zhang, G. (4) 265–271
- Hegarty, J.P., see Yu, W. (2) 83–91
- Henkhaus, R., see Dodani, S. (1) 9–19
- Hibbert, J.M., see Driss, A. (5) 295–300
- Ho, A.-S., see Cheng, C.-C. (1) 21–31
- Honsova, E., see Mohelnikova-Duchonova, B. (3) 203–210
- Horak, J., see Dostalíkova-Cimburova, M. (1) 65–72
- Hoyo, C., S.K. Murphy, J.M. Schildkraut, A.C. Vidal, D. Skaar, R.C. Millikan, J. Galanko, R.S. Sandler, R. Jirtle and T. Keku, *IGF2R* genetic variants, circulating IGF2 concentrations and colon cancer risk in African Americans and Whites (2) 133–141
- Huang, K.-J., see Cheng, C.-C. (1) 21–31
- Huang, Z., see Zhang, G. (4) 265–271
- Humphries, S.E., see Prior, S.L. (6) 363–369
- Hur, S.Y., see Zhang, G. (4) 265–271
- Hurel, S.J., see Prior, S.L. (6) 363–369
- Hussein, T.D., see El-Tayeh, S.F. (4) 255–263
- Hyacinth, H.I., see Driss, A. (5) 295–300
- Iyer, S., see Suresh, A. (1) 51–64
- Jacob, J. and P. Balaram, Molecular alterations in epidermal growth factor receptors as potential predictors of invasion in complete hydatidiform moles (CHM) (6) 371–381

- Jankovic, M., see Mitic, N. (3) 187–194
- Javidroozi, M., S. Zucker and W.-T. Chen, Plasma seprase and DPP4 levels as markers of disease and prognosis in cancer (5) 309–320
- Jiang, Q., see Yu, F. (5) 321–327
- Jindal, S.K., see Birbian, N. (5) 301–308
- Jirtle, R., see Hoyo, C. (2) 133–141
- Jirun, P., see Zhang, G. (4) 265–271
- Jones, D.A., see Prior, S.L. (6) 363–369
- Joshi, A., see Birbian, N. (5) 301–308
- Ju, C.-R., W. Liu and R.-C. Chen, Serum surfactant protein D: Biomarker of chronic obstructive pulmonary disease (5) 281–287
- Junior, M.C., see Moura, K.C.V. (3) 173–178
- Kakkar, K., see Chatterjee, A. (3) 143–151
- Kathariya, R., see Devanoorkar, A. (5) 289–294
- Kathariya, R., see Raghavendra, N.M. (6) 383–388
- Kathariya, R., see Sharma, A. (2) 101–107
- Kekatpure, V., see Suresh, A. (1) 51–64
- Keku, T., see Hoyo, C. (2) 133–141
- Kelly, A.A., see Yu, W. (2) 83–91
- Khanday, F.A., see Baba, R.A. (4) 273–279
- Kim, H.K., see Zhang, G. (4) 265–271
- Kim, J.W., see Zhang, G. (4) 265–271
- Kim, S., see Zhang, G. (4) 265–271
- Kim, T.E., see Zhang, G. (4) 265–271
- Kim, Y.W., see Zhang, G. (4) 265–271
- Knoener, M., T. Krech, F. Puls, U. Lehmann, H. Kreipe and M. Christgen, Limited value of KAI1/CD82 protein expression as a prognostic marker in human gastric cancer (6) 337–342
- Koltun, W.A., see Yu, W. (2) 83–91
- Kovac, V., see Franko, A. (2) 123–131
- Kratka, K., see Dostalikova-Cimburova, M. (1) 65–72
- Krech, T., see Knoener, M. (6) 337–342
- Kreipe, H., see Knoener, M. (6) 337–342
- Kumaran, D., see Suresh, A. (1) 51–64
- Kuriakose, M.A., see Suresh, A. (1) 51–64
- Larijani, B., see Tabaripour, R. (4) 241–246
- Lazalde-Medina, B., see Brambila-Tapia1, A.J.L. (2) 109–114
- Lee, S.-C., see Cheng, C.-C. (1) 21–31
- Lee, Y.S., see Zhang, G. (4) 265–271
- Lehmann, U., see Knoener, M. (6) 337–342
- Lei, G., see Zhang, G. (4) 265–271
- Li, J., see Chen, L. (3) 195–202
- Lin, Z., see Yu, W. (2) 83–91
- Lins, T.C.L., see Chiabai, M.A. (4) 247–253
- Liu, B., see Chen, L. (3) 195–202
- Liu, W., see Ju, C.-R. (5) 281–287
- Liu, Z., see Yu, F. (5) 321–327
- Mai, F.-D., see Cheng, C.-C. (1) 21–31
- Maillet, P., see Cherbal, F. (6) 343–353
- Mankoč, S., see Cilenšek, I. (2) 93–99
- Márquez-Martín, E., see Molina-Pinelo, S. (4) 221–230
- Martín-Juan, J., see Molina-Pinelo, S. (4) 221–230
- Masebe, T.M., P.O. Bessong, J. Nwobegahay, R.N. Ndip and D. Meyer, Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients (1) 43–50
- Mason, K., see Driss, A. (5) 295–300
- Mehdi, M.M., P. Singh and S.I. Rizvi, Erythrocyte sialic acid content during aging in humans: Correlation with markers of oxidative stress (3) 179–186
- Mena, J.P., see Brambila-Tapia1, A.J.L. (2) 109–114
- Meyer, D., see Masebe, T.M. (1) 43–50
- Millikan, R.C., see Hoyo, C. (2) 133–141
- Milutinovic, B., see Mitic, N. (3) 187–194
- Mishra, A., A. Srivastava, T. Mittal, N. Garg and B. Mittal, Impact of renin-angiotensin-aldosterone system gene polymorphisms on left ventricular dysfunction in coronary artery disease patients (1) 33–41
- Mitic, N., B. Milutinovic and M. Jankovic, Assessment of sialic acid diversity in cancer- and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs) (3) 187–194
- Mittal, B., see Mishra, A. (1) 33–41
- Mittal, T., see Mishra, A. (1) 33–41
- Mohelnikova-Duchonova, B., M. Oliverius, E. Honsova and P. Soucek, Evaluation of reference genes and normalization strategy for quantitative real-time PCR in human pancreatic carcinoma (3) 203–210
- Molina-Pinelo, S., R. Suárez, M.D. Pastor, A. Nogal, E. Márquez-Martín, J. Martín-Juan, A. Carnero and L. Paz-Ares, Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies (4) 221–230
- Moura, K.C.V., M.C. Junior, A.L.Z. de Rosso, D.H. Nicaretta, J.S. Pereira, D.J. Silva, C.B. Santos-Rebouças and M.M.G. Pimentel, Exon dosage variations in Brazilian patients with Parkinson's disease: Analysis of *SNCA*, *PARKIN*, *PINK1* and *DJ-1* genes (3) 173–178
- Mukhopadhyay, A., see Sadhukhan, T. (6) 355–362
- Murphy, S.K., see Hoyo, C. (2) 133–141
- Murugian, E.E., see Suresh, A. (1) 51–64

- Nachmany, H., S. Wald, M. Abekasis, S. Bulvik and M. Weil, Two potential biomarkers identified in mesenchymal stem cells and leukocytes of patients with sporadic amyotrophic lateral sclerosis (4) 211–220
- Naik, S.B., see Raghavendra, N.M. (6) 383–388
- Ndip, R.N., see Masebe, T.M. (1) 43–50
- Niaki, H.A., see Tabaripour, R. (4) 241–246
- Nicaretta, D.H., see Moura, K.C.V. (3) 173–178
- Nogal, A., see Molina-Pinelo, S. (4) 221–230
- Nwobegahay, J., see Masebe, T.M. (1) 43–50
- Oliverius, M., see Mohelnikova-Duchonova, B. (3) 203–210
- Park, Y.G., see Zhang, G. (4) 265–271
- Pastor, M.D., see Molina-Pinelo, S. (4) 221–230
- Patel, S.P., N.S. Rao and A.R. Pradeep, Effect of non-surgical periodontal therapy on crevicular fluid and serum glutathione peroxidase levels (1) 1–7
- Patil, S.R., see Devanoorkar, A. (5) 289–294
- Pavarino, É.C., see Zampieri, B.L. (2) 73–81
- Paz-Ares, L., see Molina-Pinelo, S. (4) 221–230
- Peralta-Leal, V., see Brambila-Tapia1, A.J.L. (2) 109–114
- Pereira, J.S., see Moura, K.C.V. (3) 173–178
- Pereira, R.W., see Chiabai, M.A. (4) 247–253
- Pérez, J.C.R., see Esparragón, F.R. (4) 231–239
- Petrovič, D., see Cilenšek, I. (2) 93–99
- Petrovič, M.G., see Cilenšek, I. (2) 93–99
- Pimentel, M.M.G., see Moura, K.C.V. (3) 173–178
- Pogue, R., see Chiabai, M.A. (4) 247–253
- Poowasanpetch, P., see Sinthuwiwat, T. (2) 115–121
- Poritz, L.S., see Yu, W. (2) 83–91
- Pradeep, A.R., see Patel, S.P. (1) 1–7
- Pradeep, A.R., see Raghavendra, N.M. (6) 383–388
- Pradeep, A.R., see Sharma, A. (2) 101–107
- Prior, S.L., A.R. Clark, D.A. Jones, S.C. Bain, S.J. Hurel, S.E. Humphries and J.W. Stephens, Association of the PGC-1 $\alpha$  rs8192678 variant with microalbuminuria in subjects with type 2 diabetes mellitus (6) 363–369
- Promso, S., see Sinthuwiwat, T. (2) 115–121
- Puls, F., see Knoener, M. (6) 337–342
- Putova, I., see Dostalíkova-Cimburova, M. (1) 65–72
- Qadri, S.K., see Baba, R.A. (4) 273–279
- Raghavendra, N.M., A.R. Pradeep, R. Kathariya, A. Sharma, N.S. Rao and S.B. Naik, Effect of non surgical periodontal therapy on gingival crevicular fluid and serum visfatin concentration in periodontal health and disease (6) 383–388
- Raghavendra, N.M., see Sharma, A. (2) 101–107
- Rao, N.S., see Patel, S.P. (1) 1–7
- Rao, N.S., see Raghavendra, N.M. (6) 383–388
- Rathore, A., see Chatterjee, A. (3) 143–151
- Ray, J., see Sadhukhan, T. (6) 355–362
- Ray, K., see Sadhukhan, T. (6) 355–362
- Ríos, N.B., see Esparragón, F.R. (4) 231–239
- Rizvi, S.I., see Mehdi, M.M. (3) 179–186
- Sadhukhan, T., M. Vishal, G. Das, A. Sharma, A. Mukhopadhyay, S.K. Das, K. Ray and J. Ray, Evaluation of the role LRRK2 gene in Parkinson's disease in an East Indian cohort (6) 355–362
- Salazar-Páramo, M., see Brambila-Tapia1, A.J.L. (2) 109–114
- Salhi, N., see Cherbai, F. (6) 343–353
- Sandler, R.S., see Hoyo, C. (2) 133–141
- Sandoval-Ramírez, L., see Brambila-Tapia1, A.J.L. (2) 109–114
- Santos-Rebouças, C.B., see Moura, K.C.V. (3) 173–178
- Schildkraut, J.M., see Hoyo, C. (2) 133–141
- Schreiber, S., see Yu, W. (2) 83–91
- Serjeant, G.R., see Driss, A. (5) 295–300
- Sezer, U., Y. Çiçek and C.F. Çanakçı, Increased salivary levels of 8-hydroxydeoxyguanosine may be a marker for disease activity for periodontitis (3) 165–172
- Sharma, A., A.R. Pradeep, N.M. Raghavendra, P. Arjun and R. Kathariya, Gingival crevicular fluid and serum cystatin c levels in periodontal health and disease (2) 101–107
- Sharma, A., see Raghavendra, N.M. (6) 383–388
- Sharma, A., see Sadhukhan, T. (6) 355–362
- Sharma, B., see Sharma, R.K. (3) 153–163
- Sharma, R.K. and B. Sharma, *In-vitro* carbofuran induced genotoxicity in human lymphocytes and its mitigation by vitamins C and E (3) 153–163
- Shishi, Q., see Zhang, G. (4) 265–271
- Silva, D.J., see Moura, K.C.V. (3) 173–178
- Singh, J., see Birbian, N. (5) 301–308
- Singh, P., see Mehdi, M.M. (3) 179–186
- Singla, N., see Birbian, N. (5) 301–308
- Sinthuwiwat, T., P. Poowasanpetch, A. Wongngamrungraj, K. Soonklang, S. Promso, C. Auewarakul and C. Tocharoentanaphol, Association of MTHFR polymorphisms and chromosomal abnormalities in leukemia (2) 115–121
- Sivadas, P., see Suresh, A. (1) 51–64
- Skaar, D., see Hoyo, C. (2) 133–141
- Song, E.Y., see Zhang, G. (4) 265–271

- Soonklang, K., see Sinthuwiwat, T. (2) 115–121
- Soucek, P., see Mohelnikova-Duchonova, B. (3) 203–210
- Srivastava, A., see Mishra, A. (1) 33–41
- Stephens, J.W., see Prior, S.L. (6) 363–369
- Stiles, J.K., see Driss, A. (5) 295–300
- Stransky, J., see Dostalickova-Cimburova, M. (1) 65–72
- Su, L., see Chen, L. (3) 195–202
- Suárez, R., see Molina-Pinelo, S. (4) 221–230
- Suresh, A., M. Vannan, D. Kumaran, Z.H. Gümüs, P. Sivadas, E.E. Murugaian, V. Kekatpure, S. Iyer, K. Thangaraj and M.A. Kuriakose, Resistance/response molecular signature for oral tongue squamous cell carcinoma (1) 51–64
- Tabaripour, R., H.A. Niaki, M.R.E. Douki, J.T. Bazzaz, B. Larijani and P. Yaghmaei, Poly thymidine polymorphism and cystic fibrosis in a non-Caucasian population (4) 241–246
- Thangaraj, K., see Suresh, A. (1) 51–64
- Tocharoentanaphol, C., see Sinthuwiwat, T. (2) 115–121
- Vannan, M., see Suresh, A. (1) 51–64
- Vannucchi, H., see Zampieri, B.L. (2) 73–81
- Vidal, A.C., see Hoyo, C. (2) 133–141
- Vidyant, S., see Chatterjee, A. (3) 143–151
- Vishal, M., see Sadhukhan, T. (6) 355–362
- Wald, S., see Nachmany, H. (4) 211–220
- Wang, H., see Yu, F. (5) 321–327
- Wang, J., see Zhang, G. (4) 265–271
- Wang, L., see Yu, F. (5) 321–327
- Wang, Y., see Yu, W. (2) 83–91
- Wani, L.A., see Baba, R.A. (4) 273–279
- Wani, M.M., see Baba, R.A. (4) 273–279
- Weil, M., see Nachmany, H. (4) 211–220
- Wilson, N.O., see Driss, A. (5) 295–300
- Wonggamrunroj, A., see Sinthuwiwat, T. (2) 115–121
- Xu, Z., see Zhang, G. (4) 265–271
- Yaghmaei, P., see Tabaripour, R. (4) 241–246
- Yan, M., see Chen, L. (3) 195–202
- Yang, Y., see Zhang, G. (4) 265–271
- Yang, Z., see Yu, F. (5) 321–327
- Yoo, J., see Zhang, G. (4) 265–271
- Yu, B., see Chen, L. (3) 195–202
- Yu, F., Q. Jiang, Y. Zhou, Z. Yang, X. Yu, H. Wang, Z. Liu, L. Wang, W. Fang and S. Guo, Abnormal expression of matrix metalloproteinase-9(MMP9) correlates with clinical course in Chinese patients with endometrial cancer (5) 321–327
- Yu, W., J.P. Hegarty, A. Berg, A.A. Kelly, Y. Wang, L.S. Poritz, A. Franke, S. Schreiber, W.A. Koltun and Z. Lin, PTPN2 is associated with Crohn's disease and its expression is regulated by NKX2-3 (2) 83–91
- Yu, X., see Yu, F. (5) 321–327
- Yu, Y., see Chen, L. (3) 195–202
- Zampieri, B.L., J.M. Biselli, E.M. Goloni-Bertollo, H. Vannucchi, V.M. Carvalho, J.A. Cordeiro and É.C. Pavarino, Maternal risk for Down syndrome is modulated by genes involved in folate metabolism (2) 73–81
- Zhang, G., S.-A. Ha, H.K. Kim, J. Yoo, S. Kim, Y.S. Lee, S.Y. Hur, Y.W. Kim, T.E. Kim, Y.G. Park, J. Wang, Y. Yang, Z. Xu, E.Y. Song, Z. Huang, P. Jirun, J. Zhongtian, Q. Shishi, C. Zhuqingqing, G. Lei and J.W. Kim, Combined analysis of AFP and HCCR-1 as an useful serological marker for small hepatocellular carcinoma: A prospective cohort study (4) 265–271
- Zheng, Y., see Chen, L. (3) 195–202
- Zhongtian, J., see Zhang, G. (4) 265–271
- Zhou, Y., see Yu, F. (5) 321–327
- Zhu, Z., see Chen, L. (3) 195–202
- Zhuqingqing, C., see Zhang, G. (4) 265–271
- Zucker, S., see Javidroozi, M. (5) 309–320